The U.S. Military’s Defense Threat Reduction Agency awarded a grant to the Texas A&M Institute for Genomic Medicine to define vaccines and drug treatments for certain toxins, viruses and bacterial pathogens.
Breakthroughs in this work will help neutralize dangerous bio-threats. “This project is broken down into three periods,” said program director Deeann Wallis. “The first period is 20 months and covers the screening phase. After that, options may be exercised such that all together it becomes a 53-month project.”
The institute is trying to define host-based targets to pathogens and toxins; the findings will be used for drug and vaccine development.
The team will be utilizing the institute’s library of mouse embryonic stem cell clones where each clone represents a single gene knockout.
“This allows us to assess gene function,” Wallis said. “We will grow and differentiate these pluripotent cells into different cell and tissue types and then challenge them with agents. Clones that show a different response will indicate which genes and proteins are involved in the body’s response to that agent. We will screen 3,500 different genes and then validate these targets in vitro and in whole animal models by making
knockout mice.”
The institute will work with toxins, bacteria and viruses to identify genes that show resistance to the threats. The team will work to develop a platform which could quickly test any toxin, virus or bacteria for bioterrorism applications.
“This is the first time something like this has been attempted,” she said. “If we can develop this unique platform to test any agent this will have a significant impact.”